AMT-116 in Patients With Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

Key facts

Study ID

NCT05725291

Run by

Multitude Therapeutics Inc.

People needed

80

Starts

2023-07-25

Expected to finish

2026-12-30

Last updated by the study team

2025-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cabrini Hospital — Victoria Park, Victoria, Australia (enrolling)
• Mary Crowley Cancer Research Centers — Dallas, Texas, United States (enrolling)
• Alfred Hospital — Victoria Park, Victoria, Australia (enrolling)
• Austin Health — Victoria Park, Victoria, Australia (enrolling)
• Carolina BioOncology Institute, LLC — Cary, North Carolina, American Samoa (enrolling)
• Macquarie University Hospital — Sydney, New South Wales, Australia (enrolling)
• ICON Cancer Centre — Brisbane, Queensland, Australia (enrolling)
• Southern Oncology Clinical Research Unit — Adelaide, South Australia, Australia (enrolling)
• University of California San Francisco Cancer Center — San Francisco, California, American Samoa
• Sarah Cannon Research Institute — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.